Do analysts prefer NVNO or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, NVNO or GCTK?

enVVeno Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enVVeno Medical N/A N/A -$19.47M -$19.33 N/A GlucoTrack N/A N/A -$19.39M -$137.63 N/A

Is NVNO or GCTK more profitable?

enVVeno Medical's return on equity of -62.28% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets enVVeno Medical N/A -62.28% -56.83% GlucoTrack N/A -2,135.52% -290.22%

Does the media favor NVNO or GCTK?

In the previous week, GlucoTrack had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 5 mentions for GlucoTrack and 3 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.72 beat GlucoTrack's score of 0.62 indicating that enVVeno Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enVVeno Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate GCTK or ICCM?

IceCure Medical has a consensus target price of $52.50, suggesting a potential upside of 2,275.57%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than GlucoTrack. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Is GCTK or ICCM more profitable?

GlucoTrack has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% IceCure Medical -427.67% -174.26% -112.58%

Does the media favor GCTK or ICCM?

In the previous week, GlucoTrack and GlucoTrack both had 5 articles in the media. GlucoTrack's average media sentiment score of 0.62 beat IceCure Medical's score of 0.49 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IceCure Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate INBS or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer INBS or GCTK?

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than GlucoTrack. MarketBeat recorded 6 mentions for Intelligent Bio Solutions and 5 mentions for GlucoTrack. Intelligent Bio Solutions' average media sentiment score of 0.82 beat GlucoTrack's score of 0.62 indicating that Intelligent Bio Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intelligent Bio Solutions 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SONX or GCTK?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonendo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SONX or GCTK more profitable?

GlucoTrack has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets Sonendo -92.74% -184.01% -68.60% GlucoTrack N/A -2,135.52% -290.22%

Do analysts recommend GCTK or BJDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GlucoTrack 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, GCTK or BJDX?

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GlucoTrack N/A N/A -$19.39M -$137.63 N/A Bluejay Diagnostics N/A N/A -$6.85M -$7.11 N/A

Is GCTK or BJDX more profitable?

Bluejay Diagnostics' return on equity of -125.00% beat GlucoTrack's return on equity. Company Net Margins Return on Equity Return on Assets GlucoTrack N/A -2,135.52% -290.22% Bluejay Diagnostics N/A -125.00% -99.79%

Does the media favor GCTK or BJDX?

In the previous week, Bluejay Diagnostics had 2 more articles in the media than GlucoTrack. MarketBeat recorded 7 mentions for Bluejay Diagnostics and 5 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.62 beat Bluejay Diagnostics' score of 0.24 indicating that GlucoTrack is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GlucoTrack 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bluejay Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

GlucoTrack (GCTK) Competitors

$2.55 -0.68 (-21.05%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.50 -0.05 (-2.04%)

As of 09/11/2026 07:59 PM Eastern

Compare

GCTK vs. NVNO, ICCM, INBS, SONX, and BJDX

Should you buy GlucoTrack stock or one of its competitors? GlucoTrack's main competitors and comparable companies include enVVeno Medical (NVNO), IceCure Medical (ICCM), Intelligent Bio Solutions (INBS), Sonendo (SONX), and Bluejay Diagnostics (BJDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does GlucoTrack compare to enVVeno Medical?

enVVeno Medical (NASDAQ:NVNO) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

In the previous week, GlucoTrack had 2 more articles in the media than enVVeno Medical. MarketBeat recorded 5 mentions for GlucoTrack and 3 mentions for enVVeno Medical. enVVeno Medical's average media sentiment score of 0.72 beat GlucoTrack's score of 0.62 indicating that enVVeno Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enVVeno Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enVVeno Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

enVVeno Medical's return on equity of -62.28% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enVVeno Medical	N/A	-62.28%	-56.83%
GlucoTrack	N/A	-2,135.52%	-290.22%

enVVeno Medical has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

enVVeno Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enVVeno Medical	N/A	N/A	-$19.47M	-$19.33	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

34.7% of enVVeno Medical shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 15.0% of enVVeno Medical shares are owned by company insiders. Comparatively, 5.9% of GlucoTrack shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

enVVeno Medical beats GlucoTrack on 9 of the 12 factors compared between the two stocks.

How does GlucoTrack compare to IceCure Medical?

GlucoTrack (NASDAQ:GCTK) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

GlucoTrack has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. IceCure Medical's return on equity of -174.26% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
IceCure Medical	-427.67%	-174.26%	-112.58%

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 5.9% of GlucoTrack shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

IceCure Medical has higher revenue and earnings than GlucoTrack. IceCure Medical is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
IceCure Medical	$3.38M	2.24	-$15.06M	-$8.52	N/A

In the previous week, GlucoTrack and GlucoTrack both had 5 articles in the media. GlucoTrack's average media sentiment score of 0.62 beat IceCure Medical's score of 0.49 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IceCure Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IceCure Medical has a consensus target price of $52.50, suggesting a potential upside of 2,275.57%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than GlucoTrack.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

GlucoTrack has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market.

Summary

IceCure Medical beats GlucoTrack on 8 of the 14 factors compared between the two stocks.

How does GlucoTrack compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by insiders. Comparatively, 5.9% of GlucoTrack shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GlucoTrack has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Intelligent Bio Solutions' return on equity of -175.35% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
GlucoTrack	N/A	-2,135.52%	-290.22%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Intelligent Bio Solutions has a beta of 4.25, meaning that its share price is 325% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Intelligent Bio Solutions has higher revenue and earnings than GlucoTrack. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.53	-$12.43M	-$9.02	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than GlucoTrack. MarketBeat recorded 6 mentions for Intelligent Bio Solutions and 5 mentions for GlucoTrack. Intelligent Bio Solutions' average media sentiment score of 0.82 beat GlucoTrack's score of 0.62 indicating that Intelligent Bio Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intelligent Bio Solutions	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Intelligent Bio Solutions beats GlucoTrack on 10 of the 13 factors compared between the two stocks.

How does GlucoTrack compare to Sonendo?

Sonendo (NYSE:SONX) and GlucoTrack (NASDAQ:GCTK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

GlucoTrack has a net margin of 0.00% compared to Sonendo's net margin of -92.74%. Sonendo's return on equity of -184.01% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
GlucoTrack	N/A	-2,135.52%	-290.22%

GlucoTrack has lower revenue, but higher earnings than Sonendo. GlucoTrack is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.14	-$60.92M	-$71.12	N/A
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A

In the previous week, GlucoTrack had 5 more articles in the media than Sonendo. MarketBeat recorded 5 mentions for GlucoTrack and 0 mentions for Sonendo. GlucoTrack's average media sentiment score of 0.62 beat Sonendo's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.

Company	Overall Sentiment
Sonendo	Neutral
GlucoTrack	Positive

Sonendo has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, GlucoTrack has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

28.7% of Sonendo shares are held by institutional investors. Comparatively, 10.9% of GlucoTrack shares are held by institutional investors. 7.9% of Sonendo shares are held by company insiders. Comparatively, 5.9% of GlucoTrack shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sonendo beats GlucoTrack on 7 of the 13 factors compared between the two stocks.

How does GlucoTrack compare to Bluejay Diagnostics?

GlucoTrack (NASDAQ:GCTK) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

GlucoTrack has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Bluejay Diagnostics' return on equity of -125.00% beat GlucoTrack's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GlucoTrack	N/A	-2,135.52%	-290.22%
Bluejay Diagnostics	N/A	-125.00%	-99.79%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlucoTrack	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlucoTrack	N/A	N/A	-$19.39M	-$137.63	N/A
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$7.11	N/A

10.9% of GlucoTrack shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 5.9% of GlucoTrack shares are held by insiders. Comparatively, 6.1% of Bluejay Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Bluejay Diagnostics had 2 more articles in the media than GlucoTrack. MarketBeat recorded 7 mentions for Bluejay Diagnostics and 5 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 0.62 beat Bluejay Diagnostics' score of 0.24 indicating that GlucoTrack is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GlucoTrack	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bluejay Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bluejay Diagnostics beats GlucoTrack on 8 of the 10 factors compared between the two stocks.

Get GlucoTrack News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GCTK vs. The Competition

Export

Metric	GlucoTrack	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.80M	$5.48B	$7.16B	$12.85B
Dividend Yield	N/A	1.80%	2.57%	11.17%
P/E Ratio	-0.02	25.09	274.94	25.36
Price / Sales	N/A	71.54	686.57	116.78
Price / Cash	N/A	32.57	76.65	51.52
Price / Book	0.06	5.97	10.33	6.20
Net Income	-$19.39M	$150.75M	$3.50B	$358.50M
7 Day Performance	-14.43%	-2.83%	-3.32%	-2.35%
1 Month Performance	-53.49%	-3.73%	-0.53%	-3.23%
1 Year Performance	-98.39%	9.38%	23.51%	8.79%

GlucoTrack Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GCTK GlucoTrack	1.1485 of 5 stars	$2.55 -21.1%	N/A	-98.4%	$1.80M	N/A	N/A	5	News Coverage Short Interest Decrease Gap Down High Trading Volume
NVNO enVVeno Medical	1.9766 of 5 stars	$11.16 -2.9%	N/A	-61.6%	$7.98M	N/A	N/A	30	News Coverage Short Interest Decrease High Trading Volume
ICCM IceCure Medical	2.7843 of 5 stars	$2.11 -4.5%	$52.50 +2,388.2%	-92.5%	$7.57M	$3.38M	N/A	60	News Coverage Short Interest Increase
INBS Intelligent Bio Solutions	1.7226 of 5 stars	$2.24 +4.2%	N/A	-88.1%	$6.51M	$4.22M	N/A	10	Short Interest Decrease
SONX Sonendo	N/A	$1.20 flat	N/A	+900.0%	$5.73M	$44.40M	N/A	250	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GCTK) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GlucoTrack (GCTK) Competitors

GCTK vs. NVNO, ICCM, INBS, SONX, and BJDX

How does GlucoTrack compare to enVVeno Medical?

Summary

How does GlucoTrack compare to IceCure Medical?

Summary

How does GlucoTrack compare to Intelligent Bio Solutions?

Summary

How does GlucoTrack compare to Sonendo?

Summary

How does GlucoTrack compare to Bluejay Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GlucoTrack (GCTK) Competitors

GCTK vs. NVNO, ICCM, INBS, SONX, and BJDX

How does GlucoTrack compare to enVVeno Medical?

Does the media favor NVNO or GCTK?

Do analysts prefer NVNO or GCTK?

Is NVNO or GCTK more profitable?

Which has more volatility & risk, NVNO or GCTK?

Which has stronger earnings and valuation, NVNO or GCTK?

Do insiders and institutionals hold more shares of NVNO or GCTK?

Summary

How does GlucoTrack compare to IceCure Medical?

Is GCTK or ICCM more profitable?

Do insiders and institutionals hold more shares of GCTK or ICCM?

Which has higher earnings & valuation, GCTK or ICCM?

Does the media favor GCTK or ICCM?

Do analysts rate GCTK or ICCM?

Which has more risk & volatility, GCTK or ICCM?

Summary

How does GlucoTrack compare to Intelligent Bio Solutions?

Do institutionals & insiders have more ownership in INBS or GCTK?

Is INBS or GCTK more profitable?

Do analysts rate INBS or GCTK?

Which has more volatility & risk, INBS or GCTK?

Which has higher valuation & earnings, INBS or GCTK?

Does the media prefer INBS or GCTK?

Summary

How does GlucoTrack compare to Sonendo?

Is SONX or GCTK more profitable?

Which has preferable valuation and earnings, SONX or GCTK?

Does the media prefer SONX or GCTK?

Which has more volatility and risk, SONX or GCTK?

Do insiders & institutionals hold more shares of SONX or GCTK?

Do analysts prefer SONX or GCTK?

Summary

How does GlucoTrack compare to Bluejay Diagnostics?

Which has more risk & volatility, GCTK or BJDX?

Is GCTK or BJDX more profitable?

Do analysts recommend GCTK or BJDX?

Which has preferable earnings and valuation, GCTK or BJDX?

Do institutionals & insiders have more ownership in GCTK or BJDX?

Does the media favor GCTK or BJDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GCTK vs. The Competition

GlucoTrack Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools